Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide,
and prognosis remains unsatisfactory when the disease is diagnosed at an advanced stage …

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …

Sorafenib, an orally-available kinase inhibitor, is the only medical treatment with a proven
efficacy against Hepatocellular Carcinoma (HCC). Although the overall clinical efficacy of …

Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma
(HCC), has opened a window of hope after searching for effective agents to combat HCC for …

Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but
its use is hampered by the occurrence of drug resistance. To investigate the molecular …

Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

BACKGROUND & AIMS: Sorafenib is the standard of care for the treatment of advanced
hepatocellular carcinoma (HCC). However, primary and acquired resistance is observed in …

It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a
significant survival benefit from the sorafenib treatment, which is currently regarded as a first …

Long‑term sorafenib treatment triggers resistance to chemotherapy in patients with
hepatocellular carcinoma (HCC). In order to investigate the mechanisms of sorafenib …